The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.a

Pneumonitis (interstitial lung disease/ILD)

Publications

Kawata T, Higashimori M, Itoh Y, Tomkinson H, Johnson MG, Tang W, Nyberg F, Jiang H, Tanigawara Y

Gefitinib exposure and occurrence of interstitial lung disease in Japanese patients with non-small-cell lung cancer.

Cancer chemotherapy and pharmacology 2019 May;83;849-858 — 2019 May — 849-858

Akamatsu H, Inoue A, Mitsudomi T, Kobayashi K, Nakagawa K, Mori K, Nukiwa T, Nakanishi Y, Yamamoto N

Interstitial lung disease associated with gefitinib in Japanese patients with EGFR-mutated non-small-cell lung cancer: combined analysis of two Phase III trials (NEJ 002 and WJTOG 3405).

Japanese journal of clinical oncology 2013 Jun;43;664-8 — 2013 Jun — 664-8

Zhang Y, Yang H, Zhao M, He J

Successful treatment of gefitinib-induced acute interstitial pneumonitis with corticosteroid and non-invasive BIPAP-ventilation.

Journal of thoracic disease 2012 Jun 01;4;316-9 — 2012 Jun 01 — 316-9

Nyberg F, Barratt BJ, Mushiroda T, Takahashi A, Jawaid A, Hada S, Umemura T, Fukuoka M, Nakata K, Ohe Y, Kato H, Kudoh S, March R, Nakamura Y, Kamatani N

Interstitial lung disease in gefitinib-treated Japanese patients with non-small-cell lung cancer: genome-wide analysis of genetic data.

Pharmacogenomics 2011 Jul;12;965-75 — 2011 Jul — 965-75

Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T,

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

The New England journal of medicine 2010 Jun 24;362;2380-8 — 2010 Jun 24 — 2380-8

Nakagawa M, Nishimura T, Teramukai S, Tada H, Tanaka F, Yanagihara K, Furuse K, Wada H, Fukushima M

Interstitial lung disease in gefitinib-treated Japanese patients with non-small cell lung cancer - a retrospective analysis: JMTO LC03-02.

BMC research notes 2009 Aug 05;2;157 — 2009 Aug 05 — 157

Kudoh S, Kato H, Nishiwaki Y, Fukuoka M, Nakata K, Ichinose Y, Tsuboi M, Yokota S, Nakagawa K, Suga M, , Jiang H, Itoh Y, Armour A, Watkins C, Higenbottam T, Nyberg F

Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study.

American journal of respiratory and critical care medicine 2008 Jun 15;177;1348-57 — 2008 Jun 15 — 1348-57

Endo M, Johkoh T, Kimura K, Yamamoto N

Imaging of gefitinib-related interstitial lung disease: multi-institutional analysis by the West Japan Thoracic Oncology Group.

Lung cancer (Amsterdam, Netherlands) 2006 May;52;135-40 — 2006 May — 135-40

Takano T, Ohe Y, Kusumoto M, Tateishi U, Yamamoto S, Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Tamura T, Kodama T, Saijo N

Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib.

Lung cancer (Amsterdam, Netherlands) 2004 Jul;45;93-104 — 2004 Jul — 93-104